T Cells of Mice Treated with mPEG-Myasthenogenic Peptide Conjugate are Involved in Protection against EAMG by Stimulating Lower Pathogenic Antibody Responses

References

• Appel S. H, Almon R. R., Levy N. Acetylcholine receptor antibodies in myasthenia gravis. N. Engl. J. Med. 1975; 293: 760–761
   PubMed Web of Science ®Google Scholar
• Lindstrom J. M, Seybold M. E, Lennon V. A., Whittingham S., Duane D. D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26: 1054–1059
   PubMed Web of Science ®Google Scholar
• Hohlfeld R., Kalies I., Kohleisen B., Heiningcr K., Conti-Tronconi B., Toyka K. V. Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 1986; 36: 618–621
   PubMed Web of Science ®Google Scholar
• Harcourt G. C, Sommcr N., Rothbard J., Willcox H. N.A., Newsom-Davis J. A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis. J. Clin. Invest. 1988; 82: 1295–1300
   PubMed Web of Science ®Google Scholar
• Oshima M., Ashizawa T., Pollack M. S., Atassi M. Z. Autoimmune T cell recognition of human acetylcholine receptor: the sites of T cell recognition in myasthenia gravis on the extracellular part of the α subunit. Eur. J. Immunol. 1990; 20: 2563–2569
   PubMed Web of Science ®Google Scholar
• Ashizawa T., Ruan K. H., Jinnai K., Atassi M. Z. Profile of the regions on the α-chain of human acetylcholine receptor recognized by autoantibodies in myasthenia gravis. Mol. Immunol. 1992; 29: 1507–1514
   PubMed Web of Science ®Google Scholar
• Pachncr A. R. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment. Yale J. biol. Med 1987; 60: 169–177
   PubMedGoogle Scholar
• Asthana D., Fujii Y., Huston G. E., Lindstrom J. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors. Clin. Immunol. Immunoputhol. 1993; 67: 240–248
   PubMedGoogle Scholar
• Ofosu-Appiah W., Mokhtarian F., Shirazian D., Grob D. Production of anti-acetylcholine receptor-a antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: role of immunoregulatory T cells and monocytes. J. Lab. Clin. Med. 1994 1124; 231: 241
   Google Scholar
• Rosenberg J. S, Oshima M., Atassi M. Z. B-cell activation In vitro by helper T cells specific to region rvl46–162 of Torpedo ealifornica nicotinic acetylcholine receptor. J. Immunol. 1996; 157: 3192–3199
   PubMed Web of Science ®Google Scholar
• Oshima M., Pachner A. R., Atassi M. Z. Profile of the regions of acetylcholine receptor α chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor. Mol. Immunol. 1994; 31: 833–843
   PubMed Web of Science ®Google Scholar
• Infante A., Thompson P. A, Krolick K. A., Wall K. A. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. J. Immunol. 1991; 146: 2977–2982
   PubMed Web of Science ®Google Scholar
• Bellone M., Ostlie N., Lei S., Wu X. D., Conti-Tronconi B. M. The I-Abm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor. J. Immunol. 1991; 147: 1484–1491
   PubMed Web of Science ®Google Scholar
• Shenoy M., Oshima M., Atassi M. Z., Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitopc-specific neonatal tolerance to synthetic region of 46 162 of acetylcholine receptor. Clin. Immunol. Immunoputhol. 1993; 66: 230–238
   PubMedGoogle Scholar
• Kaul R., Shenoy M., Goluszko E., Christadoss P. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 1994; 152: 3152–3157
   PubMed Web of Science ®Google Scholar
• Krolick K. A., Urso O. E. Analysis of helper-T cell function by acetylcholine receptor-reactive cell lines of defined AChR-subunit specificity. Cell. Immunol. 1987; 105: 75–85
   PubMed Web of Science ®Google Scholar
• Yokoi T., Mulac-Jericevic B., Kurisaki J., Atassi M. Z. T lymphocyte recognition of acetylcholine receptor: localization of the full T cell recognition profile on the extracellular part of the α chain of Torpedo ealifornica acetylcholine receptor. Eur. J. Immunol. 1987; 17: 1697–1702
   PubMed Web of Science ®Google Scholar
• Lennon V. A, McCormick D. J, Lambert E. H, Griesmann G. E., Atassi M. Z. Region of peptide 125 147 of acetylcholine receptor α subunit is exposed at the neuromuscular junction and induces experimental autoimmune myasthenia gravis, T cell immunity, and modulating autoantibodies. Proe. Natl. Acad. Sci. USA 1985; 82: 8805–8809
   PubMed Web of Science ®Google Scholar
• Lee W. Y, Sehon A. H., Akerblom E. Suppression of reaginic antibodies with modified allergens. IV. Induction of suppressor T cells by conjugates of polyethylene glycol (PEG) and monomethoxy PEG with ovalbumin. Int. Archs Allergy appl. Immune. 1981; 64: 100–114
   PubMedGoogle Scholar
• Mokashi S., Holford-Strevens V., Sterrantino G., Jackson C. J.C., Sehon A. H. Down-regulation of secondary in vitro antibody responses by suppressor T cells of mice treated with a tolerogenic conjugate of ovalbumin and monomethoxypolyethylene glycol, OVA(mPEG)i.v. Immunol. Lett 1989; 23: 95–102
   PubMedGoogle Scholar
• Atassi M. Z, Ruan K. H., Jinnai K., Oshima M., Ashizawa T. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc. Natl. Acad. Sci. USA 1992; 89: 5852–5856
   PubMed Web of Science ®Google Scholar
• Mulac-Jericevic B., Kurisaki J., Atassi M. Z. Profile of the continuous antigenic regions on the extracellular part of the α chain of an acetylcholine receptor. Proc. Natl. Acad. Sci. USA 1987; 84: 3633–3637
   PubMed Web of Science ®Google Scholar
• Mulac-Jericevic B., Atassi M. Z. α-Neurotoxin binding to acetylcholine receptor: localization of the full profile of the cobratoxin-binding regions on the a-chain of Torpedo californica acetylcholine receptor by a comprehensive synthetic strategy. J. Prot. Chem. 1987; 6: 365–373
   Google Scholar
• McCormick D. J., Atassi M. Z. Localization and synthesis of the acetylcholine-binding site in the α-chain of the Torpedo californica acetylcholine receptor. Biochem. J. 1984; 224: 995–1000
   PubMed Web of Science ®Google Scholar
• Oshima M., Atassi M. Z. Effect of amino acid substitutions within the region 62 76 of 1-βb on binding with and antigen presentation of Torpedo acetylcholine receptor o-chain peptide 146 162. J. Immunol. 1995; 154: 5245–5254
   PubMed Web of Science ®Google Scholar
• Shenoy M., Goluszko E., Christadoss P. The pathogenic role of acetylcholine receptor o chain epitope within o 146 162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin. Immunol, lmmunopathol. 1994; 73: 338–343
   PubMedGoogle Scholar
• Adorini L., Barnaba V., Bona C, Celada P., Lanzavecchia A., Sercarz E., et al. New perspectives on immunointervention in autoimmune diseases. Immunol. Today 1990; 11: 383–386
   PubMedGoogle Scholar
• Chen Y., Takata M., Maiti P. K, Rector E. S., Sehon A. H. Characterization of suppressor T cell clones derived from a mouse tolerized with conjugates of ovalbumin and monomethoxypolyethylene glycol. Cell. Immunol. 1992; 142: 16–27
   PubMedGoogle Scholar